HIV Glasgow 2020

The 2020 International Congress on Drug Therapy in HIV Infection (HIV Glasgow) took place from 5 to 8 October 2020. It was held virtually this year due to the coronavirus.

Injectable & long-acting HIV treatment

Long-acting injectables work without oral lead-in period

11 October 2020

Clinical trials

Biological, clinical and ethical imperatives for involving diverse women in HIV clinical trials

14 October 2020

Injectable & long-acting HIV treatment

New once-a-week drug could be part of weekly oral treatment

13 October 2020

Cardiovascular disease

High blood pressure less common in people with HIV in Africa

13 October 2020

Access to healthcare

European AIDS Treatment Group documents the impact of COVID on HIV services throughout Europe

12 October 2020

New & experimental HIV treatments

Islatravir plus doravirine remains effective at 96 weeks

9 October 2020

Sleep

Promising results for programme to reduce sleep disturbance in people with HIV

8 October 2020

Weight gain & lipodystrophy

Weight gain after switch to an integrase inhibitor does not boost 'bad fat'

7 October 2020

Injectable & long-acting HIV treatment

Injectable HIV therapy should save money if adherence is better than to oral therapies

7 October 2020

Weight gain & lipodystrophy

Weight gain on HIV treatment: what is normal, and what is harmful?

7 October 2020

Injectable & long-acting HIV treatment

Two-thirds of people living with HIV would like to try injectable treatment, according to European survey

5 October 2020

Conference bulletins

English

News from the International Congress on Drug Therapy in HIV Infection (HIV Glasgow 2020)

(HTML)

Russian

Новости c Международного конгресса по антиретровирусной терапии (ВИЧ Глазго 2020)

(HTML)

Spanish

Noticias del Congreso Internacional sobre sobre Terapia Farmacológica del VIH (HIV Glasgow 2020)

(HTML)

French

L’actualité du Congrès international sur la pharmacothérapie du VIH (HIV Glasgow 2020)

(HTML)

Portuguese

Notícias do Congresso Internacional sobre Tratamentos para a infeção pelo VIH (HIV Glasgow 2020)

(HTML)

Italian

Notizie dalla Conferenza Internazionale sulla Farmacoterapia nell'infezione da HIV (HIV Glasgow 2020)

(HTML)

Editors’ picks from other sources

New & experimental HIV treatments

Capsid inhibitor lenacapavir, dosed six-monthly, has high barrier to drug resistance and no cross-resistance to other classes

New data at the Glasgow conference on the capsid inhibitor lenacapavir included results on drug resistance. Although two participants in a proof-of-concept phase 1b dose finding study on each of the lowest doses developed a single resistance mutation, this will be overcome at the higher doses used for phase2/3 development.

i-Base

9 Oct 20

Treatment simplification strategies

GSK's ViiV, armed with long-term Dovato data, eyes 'tipping point' for 2-drug HIV regimen

Changing over two decades of treatment practice can be laborious. For ViiV Healthcare, the process involves delivering long-term data to prove its two-drug HIV regimens work just well as traditional triplets over time. Now, the GlaxoSmithKline subsidiary believes it has the results to boost confidence among doctors and move closer to a major growth boost.

FiercePharma

7 Oct 20

HIV Glasgow 2020

Long-acting injectables work without oral lead-in period

Biological, clinical and ethical imperatives for involving diverse women in HIV clinical trials

New once-a-week drug could be part of weekly oral treatment

High blood pressure less common in people with HIV in Africa

European AIDS Treatment Group documents the impact of COVID on HIV services throughout Europe

Islatravir plus doravirine remains effective at 96 weeks

Promising results for programme to reduce sleep disturbance in people with HIV

Weight gain after switch to an integrase inhibitor does not boost 'bad fat'

Injectable HIV therapy should save money if adherence is better than to oral therapies

Weight gain on HIV treatment: what is normal, and what is harmful?

Two-thirds of people living with HIV would like to try injectable treatment, according to European survey

Conference bulletins

English

News from the International Congress on Drug Therapy in HIV Infection (HIV Glasgow 2020)

Russian

Новости c Международного конгресса по антиретровирусной терапии (ВИЧ Глазго 2020)

Spanish

Noticias del Congreso Internacional sobre sobre Terapia Farmacológica del VIH (HIV Glasgow 2020)

French

L’actualité du Congrès international sur la pharmacothérapie du VIH (HIV Glasgow 2020)

Portuguese

Notícias do Congresso Internacional sobre Tratamentos para a infeção pelo VIH (HIV Glasgow 2020)

Italian

Notizie dalla Conferenza Internazionale sulla Farmacoterapia nell'infezione da HIV (HIV Glasgow 2020)

Switching HIV Regimen to Biktarvy Is Safe and Effective for the Long Term

Over Half in UK HIV Women's Study Report Moderate or Severe Pain

Highest Cancer Risk in HIV+ Current Smokers and Those With Poor HIV Control

Multidrug Resistance Still Boosts Death Risk in 31,000-Person Italian Study

Capsid inhibitor lenacapavir, dosed six-monthly, has high barrier to drug resistance and no cross-resistance to other classes

GSK's ViiV, armed with long-term Dovato data, eyes 'tipping point' for 2-drug HIV regimen